Skip to content

BAMF Health Clinical Trials

BAMF Health’s patients have the opportunity to participate in the most advanced clinical trials available. Please select the option below that is most appropriate to your individual needs and follow the link to our intake form.

 

Available Clinical Trials

BAMF Health is currently recruiting for the following advanced clinical trials 

Prostate Cancer | Lantheus EAP Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Protocol Title: Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sponsor: Lantheus Medical Imaging, Inc.

Description: The purpose of this program is to provide access to [Lu-177]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials.

In this program participants will be administered [Lu-177]-PNT2002 intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. During treatment, participants will be monitored with routine laboratory tests such as:

• Hematology blood tests
• Clinical Chemistry blood tests
• Testosterone/Prostate Antigen levels blood test
• Vital signs
• Imaging
• ECG

Patient Enrollment at BAMF: Recruiting Now

Number of patients to be enrolled (study wide): 250

Patient Eligibility Criteria: please click here to see the complete list

If you are interested in more information about this trial, please fill out this form.

Prostate Cancer | COMBAT Trial A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617

Protocol Title: A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617

Short Name: COMBAT Trial

Sponsor: Clarity Pharmaceuticals Ltd

Description: The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.

Patient Enrollment at BAMF: Recruiting Now

Number of patients to be enrolled (study wide): 38 participants

Patient Eligibility Criteria: please click here to see the complete list

If you are interested in more information about this trial, please fill out this form.

Pancreatic Cancer | NMK89P101 Trial Assess safety, tolerability, pharmacokinetics, radiation dosimetry, and positron emission tomography (PET) imaging properties of 89Zr-labeled hNd2

Title: A Phase I trial to assess safety, tolerability, pharmacokinetics, radiation dosimetry, and positron emission tomography (PET) imaging properties of 89Zr-labeled hNd2 (NMK89) in patients with pancreatic cancer histologically positive for MUC5AC

Short Name: NMK89P101

Sponsor: Nihon Medi-Physics

Number of patients to be enrolled study wide: 10

Patient enrollment at BAMF: recruiting now

Patient eligibility criteria: https://clinicaltrials.gov/study/NCT06129422

If you are interested in more information about this trial, please fill out this form

Pancreatic Cancer | FAPI-46 Trial A Phase 2, Multicenter, Single Arm, Open Label Non-Randomized Study of [68Ga]FAPI-46 PET in Patients With Resectable or Borderline Resectable Pancreatic Ductal Carcinoma

Protocol Title: Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma (FAPI-46 PDAC)

Sponsor: SOFIE Biosciences

Description: This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. This will be followed by histopathology and IHC analyses and comparison to resected PDAC tumor specimens.

Patient Enrollment at BAMF: Recruiting Now

Number of patients to be enrolled (study wide): 60

Patient Eligibility Criteriaplease click here to see the complete list

To get more information or to be connected to discuss this clinical trial with someone at BAMF Health, please complete this form

Gastrointestinal Cancers | FAPI-74 Trial Assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers

Title: A Phase 2, Multicenter, Single Arm, Open Label, Non-Randomized Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

Short Name: FAPI-74 / 18FFAPI-2023P2

Sponsor: SOFIE

Description: This is a prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the primary objective) and histopathology (as the secondary objective) of the biopsied or resected tissues.

Number of patients to be enrolled study wide: 120

Patient enrollment at BAMF: recruiting now

Patient eligibility criteria: https://clinicaltrials.gov/study/NCT05641896

To get more information or to be connected to discuss this clinical trial with someone at BAMF Health, please complete this form

Adrenal Gland Disorders/Healthy volunteers | FNP-59 Trial Investigating if [18F]FNP-59 can be useful in capturing PET/CT images of the adrenal gland

Title: Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59

Short Name: FNP-59

Sponsor: University of Michigan

Description: We are trying to understand if an imaging agent (also known as a PET Tracer) called [18F]FNP-59 can be useful in taking pictures (PET/CT images) of the adrenal gland to help diagnose disorders.  The adrenal gland is a small organ that sits on top of each kidney. It produces hormones that are important for regulating blood pressure, blood sugar, and other bodily functions. This imaging agent is special because it doesn’t have the same risks as the current imaging agent, which can sometimes damage the thyroid gland. We hypothesize that [18F]FNP-59 will be more effective than current imaging at determining if there is an adrenal gland disorder and may prevent the need for more invasive procedures for patients.

  • Healthy volunteers and people with adrenal gland disorders are able to participate in this trial.
  • Healthy participants in this study will receive a medication by IV that will stimulate their adrenal gland and hormones, and then will receive an injection by IV the [18F]FNP-59 PET tracer and have multiple PET/CT scans.
  • Participants with Adrenal Gland Disorders will receive an injection by IV of [18F]FNP-59 and have multiple PET/CT scans.

Number of patients to be enrolled study wide: 24

Patient enrollment at BAMF: recruiting now

Patient eligibility criteria: https://clinicaltrials.gov/study/NCT0454612

If you are interested in more information about this trial, please fill out this form.

Future Clinical Trials

BAMF Health is working every day to bring on additional clinical trials opportunities to improve disease management using molecular imaging and molecularly targeted radiation therapy.

Please fill out this form if you are interested to receive updates when BAMF Health initiates a clinical trial that matches your interests.